HomeCompareAPTO vs PLD

APTO vs PLD: Dividend Comparison 2026

APTO yields 116.96% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APTO wins by $1.11M in total portfolio value
10 years
APTO
APTO
● Live price
116.96%
Share price
$1.71
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$7.61M
Annual income
$2,839,061.37
Full APTO calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — APTO vs PLD

📍 APTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPTOPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APTO + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APTO pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APTO
Annual income on $10K today (after 15% tax)
$9,941.52/yr
After 10yr DRIP, annual income (after tax)
$2,413,202.16/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PLD beats the other by $2,054,768.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APTO + PLD for your $10,000?

APTO: 50%PLD: 50%
100% PLD50/50100% APTO
Portfolio after 10yr
$7.06M
Annual income
$4,047,748.78/yr
Blended yield
57.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

APTO
Analyst Ratings
10
Buy
1
Hold
Consensus: Buy
Altman Z
-114.1
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APTO buys
0
PLD buys
0
No recent congressional trades found for APTO or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPTOPLD
Forward yield116.96%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$7.61M$6.50M
Annual income after 10y$2,839,061.37$5,256,436.18
Total dividends collected$6.91M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: APTO vs PLD ($10,000, DRIP)

YearAPTO PortfolioAPTO Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$22,396$11,695.91$11,255$555.24+$11.1KAPTO
2$48,444$24,480.41$13,062$1,018.59+$35.4KAPTO
3$101,324$49,488.77$15,903$1,926.67+$85.4KAPTO
4$205,154$96,737.39$20,839$3,823.32+$184.3KAPTO
5$402,568$183,053.76$30,464$8,166.08+$372.1KAPTO
6$766,451$335,702.65$52,054$19,457.30+$714.4KAPTO
7$1,417,434$597,331.71$109,886$54,188.93+$1.31MAPTO
8$2,549,060$1,032,405.58$304,030$186,451.18+$2.25MAPTO
9$4,462,671$1,735,176.87$1,166,125$840,813.32+$3.30MAPTO
10$7,614,120$2,839,061.37$6,504,190$5,256,436.18+$1.11MAPTO

APTO vs PLD: Complete Analysis 2026

APTOStock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.

Full APTO Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this APTO vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APTO vs SCHDAPTO vs JEPIAPTO vs OAPTO vs KOAPTO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.